Jiangsu Apon Medical Technology Co., Ltd.
SZSE:300753.SZ
16.55 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 417.981 | 323.808 | 461.211 | 443.076 | 379.647 | 298.034 | 246.922 | 198.302 | 153.516 | 120.351 |
| Cost of Revenue
| 161.375 | 163.759 | 166.332 | 188.593 | 112.019 | 70.035 | 62.282 | 50.945 | 40.125 | 33.878 |
| Gross Profit
| 256.606 | 160.049 | 294.879 | 254.483 | 267.628 | 227.999 | 184.641 | 147.356 | 113.39 | 86.473 |
| Gross Profit Ratio
| 0.614 | 0.494 | 0.639 | 0.574 | 0.705 | 0.765 | 0.748 | 0.743 | 0.739 | 0.719 |
| Reseach & Development Expenses
| 32.154 | 34.946 | 43.981 | 23.552 | 24.497 | 20.983 | 20.026 | 15.357 | 9.777 | 6.718 |
| General & Administrative Expenses
| 31.621 | 22.514 | 38.48 | 20.9 | 21.992 | 24.765 | 19.332 | 19.607 | 26.038 | 24.668 |
| Selling & Marketing Expenses
| 147.71 | 142.605 | 126.33 | 91.436 | 103.461 | 81.566 | 63.183 | 47.878 | 37.741 | 24.307 |
| SG&A
| 224.993 | 165.118 | 164.809 | 112.335 | 125.453 | 106.331 | 82.514 | 67.485 | 63.779 | 48.975 |
| Other Expenses
| 0.876 | -2.386 | -0.487 | -1.62 | -2.907 | -1.824 | -0.938 | 8.374 | 6.094 | 4.205 |
| Operating Expenses
| 256.27 | 231.974 | 235.496 | 146.339 | 171.874 | 141.42 | 115.021 | 100.728 | 85.152 | 50.469 |
| Operating Income
| 0.336 | -88.324 | 55.788 | 113.532 | 120.73 | 85.559 | 70.694 | 49.112 | 27.344 | 34.797 |
| Operating Income Ratio
| 0.001 | -0.273 | 0.121 | 0.256 | 0.318 | 0.287 | 0.286 | 0.248 | 0.178 | 0.289 |
| Total Other Income Expenses Net
| 14.657 | -2.386 | -0.487 | -1.62 | -2.907 | -1.824 | -0.938 | 8.374 | 6.094 | 4.205 |
| Income Before Tax
| 14.993 | -90.709 | 55.3 | 111.912 | 117.823 | 83.735 | 69.756 | 57.486 | 33.438 | 39.001 |
| Income Before Tax Ratio
| 0.036 | -0.28 | 0.12 | 0.253 | 0.31 | 0.281 | 0.283 | 0.29 | 0.218 | 0.324 |
| Income Tax Expense
| 5.359 | -14.161 | 1.982 | 15.04 | 14.985 | 12.655 | 9.558 | 8.181 | 3.736 | 6.832 |
| Net Income
| 8.277 | -76.377 | 54.064 | 96.959 | 102.343 | 70.09 | 57.922 | 47.703 | 28.899 | 31.384 |
| Net Income Ratio
| 0.02 | -0.236 | 0.117 | 0.219 | 0.27 | 0.235 | 0.235 | 0.241 | 0.188 | 0.261 |
| EPS
| 0.066 | -0.61 | 0.43 | 0.77 | 0.81 | 0.74 | 0.62 | 0.51 | 0.23 | 0.75 |
| EPS Diluted
| 0.066 | -0.61 | 0.43 | 0.77 | 0.81 | 0.74 | 0.62 | 0.51 | 0.23 | 0.75 |
| EBITDA
| 23.765 | -51.273 | 78.708 | 124.63 | 108.317 | 97.319 | 78.606 | 64.755 | 37.7 | 37.024 |
| EBITDA Ratio
| 0.057 | -0.158 | 0.171 | 0.281 | 0.285 | 0.327 | 0.318 | 0.327 | 0.246 | 0.308 |